CTOs on the Move

Advanced Research Projects Agency for Health

www.arpa-h.gov

 
The Advanced Research Projects Agency for Health (ARPA-H) is committed to solving the most challenging problems in health by developing research programs dedicated to urgency, excellence and honesty. Part of the U.S. Department of Health and Human Services, ARPA-H aims to accelerate breakthroughs that empower every American to realize their full health potential – turning the seemingly impossible to the possible to the actual. The ARPA model is a continuous cycle of planning, implementing, and evaluating, and we`re looking for the best ideas and the brightest minds to carry out each process. We`re committed to diversity in all its forms.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Kevin Duvall
ARPA-H Chief Information Officer Profile
Kevin Duvall
Acting Chief Technology Officer and Chief Information Officer Profile

Similar Companies

Advanced Solutions

Advanced Solutions designs and manufactures biofabrication systems for next-generation drug discovery, personalized medicine, and regenerative therapeutics.

Pharmgate

Pharmgate Animal Health is headquartered in Wilmington, North Carolina, and provides innovative and high-quality products that help the livestock industry optimize animal health, efficiency and production. Pharmgate Animal Health is celebrating its 10th Anniversary in 2018. The company`s pharmaceutical production facilities are located in Omaha, Nebraska with vaccine research and manufacturing operations based in St. Paul, Minnesota.

RubrYc Therapeutics

RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.

Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Our integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. We are able to target a broad variety of epigenetic regulators using our platform and have generated development candidates acting against distinct classes of those regulators.

Senti Bio

Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address.